How common is delayed cyclosporine absorption following liver transplantation?

Liver Transplantation

Volumn 11, Issue 2, 2005, Pages 167-173

  Yantorno, Silvina E ^a   Varela, Eva B ^a   Raffa, Sebastián R ^a   Descalzi, Valeria I ^a   Carretero, Maria L Gomez ^a   Pirola, Daniel A ^a   Ruf, Andres E ^a   Carabuz, Gretel I Martinez ^a   Podesta, Luis G ^a   Villamil, Federico G ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALE; NEPHROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT;

ADULT; AGED; CYCLOSPORINS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 20944449226     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20341     Document Type: Article

References (15)

1. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection. Transplantation 1999;67:1133-1137.
2. 2). Transplantation 2002;73:953-959.
3. Dunn SP. Neoral monitoring 2 hours post-dose and the pediatric transplant patient. Pediatr Transplant 2003;7:25-30.
4. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998;66:1621-1627.
5. 4 in long-term liver transplant recipients. Transplant Proc 2002;34:1535-1537.
6. Lück R, Böger J, Kuse E, Klempnauer J, Nashan B. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy. Liver Transpl 2004;10:686-691.
7. Kovarik JM, Rouilly M, Soergel M, Cornu-Artis C. Neoral C2 remains a robust marker of cyclosporine exposure regardless if it is used in regimens with MMF, azathioprine, everolimus or FTY720 [Abstract 274]. Am J Transplant 2004;4(Suppl 8):233.
8. 2 monitoring are sustained at 1 year in de novo liver transplant recipients. Transplant Proc 2001; 33:3092-3093.
9. 2 monitoring: an international consensus statement. Transplantation 2002;73(Suppl):S12-S18.
10. 0 monitoring in de novo liver transplantation. LIS2T Study Group. Transplantation 2004;77:1632-1638.
11. 2 monitoring versus tacrolimus in liver transplantation (LIS2T) [Abstract 400]. Am J Transplant 2004;4(Suppl 8):268.
12. 2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl 2004;10:577-583.
13. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999;68:55-62.
14. Glanemann M, Klup J, Langrehr JM, Schröer G, Platz KP, Stange B, et al. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. Transplant Proc 2000;32;522-523.
15. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, et al. Unexpected augmentation of mycophenolate acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997;5:225-232.